Who Are The Key Hemato-Oncology Market Stakeholders?

As a marketing professional in the healthcare industry, you need to accurately identify the criteria that define your specific target population in order to size your market and build your strategy. You also need to be aware of the individuals and organizations who shape the patient journey, any challenges specific to disease management and who the choice drivers are. Identifying the appropriate stakeholders and staying up to date on their roles and characteristics is therefore crucial. This post explores the different stakeholder groups in this rapidly evolving market.



 To find out more about the fast moving therapeutic area of hemato-oncology  download our eBook here.


1. Onco-Hematology Medical Professionals

 Defining and mapping the onco-hematology universe is complex:

  • Surprisingly, hemato-oncologist training differs greatly from one country to another. In some countries, such as Germany, Ireland, Iceland and Albania, it is a real specialty. In other countries, training is integrated into general training, or into an oncology diploma, and is not always compulsory as is the case in Greece.
  • In most countries, there is neither an exact description of the population of hemato- oncologists nor baseline data to provide a precise description of these practitioners available, yet this information is necessary to define and size this specific market.
  • As with the solid tumor oncologists, the practice of hemato-oncologists may differ greatly from one country to another. For example, the proportion of hemato-oncologists practicing in private practice is high in Germany when compared to France.
  • Within the domain of hemato-oncology, Key Opinion Leaders (KOLs) play a key role in influencing patient care treatment algorithms, for example. In some cases, highly homogenous practices in their “area” of influence can be observed.



Robert Z. Olowski is number one influencer in the Multiple Myeloma field according to the Brandwatch Impact Score.


2. Professional Associations

Professional associations aim to promote the sharing of knowledge, best practice and experiences in the field of onco-hematology for areas including research, patient care, and training. They are key stakeholders in the market. 

Here are some key professional associations to note:


3. Patient Associations

Each blood cancer disease has a wide range of linked patient associations that are active stakeholders. Patient associations within this therapeutic area:

  • Assist and inform patients and their families throughout care pathways and in managing daily life
  • Develop partnerships
  • Act as interlocutors with health authorities
  • Support research and share recent news

Example patient associations:

  • The European Hematology Association (EHA) - Europe – www.ehaweb.org/ European Hematology Association
  • MDS Alliance – Europe - https://www.mds-alliance.org/member-organizations/the global MDS patient network
  • AF3M – France - https://www.af3m.org
  • France Lymphome Espoir – France - https://www.francelymphomeespoir.fr

 Additional links are listed here.


3. Pharmaceutical and Biotech Companies


The capabilities of biotechnologies such as cell therapies, gene therapies, and immunotherapies are rapidly improving, and leading pharmaceutical companies are eager to integrate them. Novartis just acquired American gene therapy specialist AveXis. Merck, Roche and Astra Zeneca are significantly investing in immunotherapy, while Bayer has created BlueRock Therapeutics for treatments based on stem cells. Mergers are also accelerating in immunotherapy start-ups: Gilead Sciences just acquired Kite Pharma and Celgene procured Juno Therapeutics. Big pharma aside, it is also important to follow young biotechnology companies.

Example pharmaceutical companies:


Do you still have specific questions regarding the hemato-oncology market? Our market specialists are currently offering 30-minute free consultation calls that give you the opportunity to ask any questions you may have on about the market. 

Arrange a call



Sources :

AplusA Research


 You might also be interested in:

       5 Benefits of Syndicated Research in the Hematology Oncology Market

       Blood Cancer Treatments: Current and Future